Upsher-Smith Laboratories LLC, a United States-based pharmaceutical company, has introduced its Ramelteon Tablets, 8mg, it was reported on Tuesday.
Upsher-Smith's product is AB-rated to the branded product, ROZEREM (ramelteon) tablets. The product is intended for the treatment of insomnia characterised by difficulty with sleep onset.
Rusty Field, president and CEO, Upsher-Smith, said, 'Expanding Upsher-Smith's portfolio of generic drug products and providing patients access to affordable generic medicines continues to be a priority. The launch of Ramelteon, the company's sixth generic product launch this year, clearly demonstrates the incredible resolve of our team in helping achieve these milestones during an unprecedented time.'
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US